



Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)

April 19, 2026

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)

Authors: French, JA et al.